Form 4: SOPHIA GENETICS SA: Insider Sells Shares for Tax Withholding

Daan Van Well, Chief Legal Officer of SOPHiA GENETICS SA, sold a total of 4,849 ordinary shares across two transactions to cover tax obligations related to vested restricted stock units.

Summary

• Daan Van Well, Chief Legal Officer of SOPHiA GENETICS SA, reported the sale of 2,861 ordinary shares on April 8, 2026, and 1,988 ordinary shares on April 9, 2026.
• These sales were conducted to satisfy tax withholding obligations arising from the vesting of restricted stock units on April 2 and 3, 2026.
• The transactions were executed under a Rule 10b5-1 trading plan, indicating they were pre-arranged and not discretionary.
• The weighted average selling price for the April 8 transaction was $4.8452, with individual sales ranging from $4.78 to $4.94.
• The weighted average selling price for the April 9 transaction was $4.7406, with individual sales ranging from $4.61 to $4.86.
• Following these transactions, Daan Van Well beneficially owns 348,820 ordinary shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While insider selling can be a negative signal, the clear explanation of tax withholding obligations and the use of a Rule 10b5-1 plan mitigate significant concern.

Positives

• The sales were executed under a Rule 10b5-1 trading plan, which is a standard and compliant method for insiders to sell shares while avoiding insider trading concerns.
• The transactions were for the purpose of covering tax withholding obligations, a common and necessary event for executives upon vesting of equity awards.

Negatives

• Insider selling, even for tax purposes, can sometimes be perceived negatively by the market, potentially impacting short-term stock sentiment.
• The weighted average selling prices indicate a slight downward trend in the stock price between the two transaction dates.

Risks

• The primary risk is the potential negative market perception of insider selling, regardless of the reason.
• Fluctuations in the stock price could impact the actual tax liability and the number of shares required to cover it.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports on past transactions.

Management Comments

• The sales were effected pursuant to a pre-established Rule 10b5-1 trading plan adopted by the Reporting Person and do not represent discretionary trades.
• The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Industry Context

StockSavvy.ai notes that Form 4 filings are routine disclosures for publicly traded companies, detailing changes in beneficial ownership by insiders. The use of a Rule 10b5-1 plan by Daan Van Well is a common practice to manage equity sales for personal financial planning and tax obligations while adhering to regulatory requirements.

Stakeholder Impact

• Shareholders: May observe a slight negative sentiment due to insider selling, though the tax-related nature and Rule 10b5-1 plan should temper concerns.
• Employees: No direct impact expected, as this is an executive-level financial transaction.
• Creditors: No impact expected.
• Suppliers: No impact expected.

Next Steps

• The reporting person will continue to hold the remaining 348,820 ordinary shares.
• The company will continue its operations as a biotechnology company focused on genomic data analysis.

Key Dates

Keywords

SOPHiA GENETICS SA, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Rule 10b5-1, Beneficial Ownership, Daan Van Well, Chief Legal Officer